June 5, 2024 11:37 AM EDTUpdated 12:00 PM
R&D
Manufacturing

Rayze­Bio warned of po­ten­tial iso­tope sup­ply is­sues be­fore BMS deal

Kyle LaHucik

Senior Reporter

Lei Lei Wu

News Reporter

Rayze­Bio ad­vised in­vestors last year it could face prob­lems se­cur­ing ac­tini­um iso­tope from a Russ­ian sup­pli­er that it re­lies on for in­ter­na­tion­al stud­ies.

Bris­tol My­ers …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

GSK plots reg­u­la­to­ry fil­ings for PBC itch af­ter pos­i­tive Phase 3 read­out

Chi­nese drug­mak­er re­ceives FDA warn­ing let­ter af­ter man­age­ment hin­dered in­spec­tion

Bio­gen, UCB de­tail re­sponse rates in Phase 3 lu­pus tri­al af­ter sur­pris­ing suc­cess

J&J, Pro­tag­o­nist re­veal two Phase 3 wins for oral IL-23 drug that's ex­pect­ed to be a block­buster

FDA re­jects Astel­las’ ef­fort to sup­port longer use of eye drug Iz­er­vay 

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times